Mikko Hakola

1.2k total citations
8 papers, 300 citations indexed

About

Mikko Hakola is a scholar working on Rheumatology, Infectious Diseases and Pharmacology. According to data from OpenAlex, Mikko Hakola has authored 8 papers receiving a total of 300 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Rheumatology, 1 paper in Infectious Diseases and 1 paper in Pharmacology. Recurrent topics in Mikko Hakola's work include Rheumatoid Arthritis Research and Therapies (5 papers), Systemic Lupus Erythematosus Research (3 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (1 paper). Mikko Hakola is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (5 papers), Systemic Lupus Erythematosus Research (3 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (1 paper). Mikko Hakola collaborates with scholars based in Finland. Mikko Hakola's co-authors include Pekka Hannonen, Timo Möttönen, Martti Oka, Marjatta Leirisalo‐Repo, Hannu Kautiainen, Markku Korpela, Leena Laasonen, Tuulikki Sokka, Harri Blåfield and Heidi Mäkinen and has published in prestigious journals such as Annals of the Rheumatic Diseases, Scandinavian Journal of Rheumatology and Arthritis & Rheumatism.

In The Last Decade

Mikko Hakola

7 papers receiving 285 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mikko Hakola Finland	6	246	105	49	48	29	8	300
Samina A. Turk Netherlands	10	187 0.8×	55 0.5×	23 0.5×	30 0.6×	77 2.7×	23	287
Laurette van Boheemen Netherlands	11	230 0.9×	55 0.5×	24 0.5×	25 0.5×	51 1.8×	22	322
S. Amarger France	7	132 0.5×	25 0.2×	55 1.1×	106 2.2×	41 1.4×	14	380
Motohiro Oribe Japan	10	185 0.8×	98 0.9×	32 0.7×	13 0.3×	100 3.4×	15	330
Émeline Minichiello France	5	180 0.7×	46 0.4×	16 0.3×	27 0.6×	56 1.9×	9	300
M J Grange France	6	84 0.3×	115 1.1×	128 2.6×	111 2.3×	64 2.2×	11	327
Mitra Pikwer Sweden	6	241 1.0×	26 0.2×	22 0.4×	53 1.1×	69 2.4×	9	335
Е. Л. Лучихина Russia	8	195 0.8×	77 0.7×	10 0.2×	13 0.3×	58 2.0×	69	288
Jaroslava Vaněčková Czechia	12	66 0.3×	34 0.3×	19 0.4×	28 0.6×	87 3.0×	33	406
Ignacio García-Valladares United States	10	126 0.5×	47 0.4×	12 0.2×	27 0.6×	105 3.6×	16	252

Countries citing papers authored by Mikko Hakola

Since Specialization

Citations

This map shows the geographic impact of Mikko Hakola's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mikko Hakola with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mikko Hakola more than expected).

Fields of papers citing papers by Mikko Hakola

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mikko Hakola. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mikko Hakola. The network helps show where Mikko Hakola may publish in the future.

Co-authorship network of co-authors of Mikko Hakola

This figure shows the co-authorship network connecting the top 25 collaborators of Mikko Hakola. A scholar is included among the top collaborators of Mikko Hakola based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mikko Hakola. Mikko Hakola is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Rantalaiho, Vappu, Hannu Kautiainen, Markku Korpela, et al.. (2013). Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial. Annals of the Rheumatic Diseases. 73(11). 1954–1961. 44 indexed citations

Kauppinen, Risto A., et al.. (2012). Hiehonkasvatuksen ulkoistaminen - Opas kasvattajalle ja ulkoistajalle. Jukuri (Natural Resources Institute Finland (Luke)).

Mäkinen, Heidi, Hannu Kautiainen, Pekka Hannonen, et al.. (2007). Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis.. PubMed. 34(2). 316–21. 97 indexed citations

Kuuliala, Antti, Marjatta Leirisalo‐Repo, Timo Möttönen, et al.. (2005). Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drug.. PubMed. 23(2). 243–6. 9 indexed citations

Hannonen, Pekka, Timo Möttönen, Mikko Hakola, & Martti Oka. (1993). Sulfasalazine in early rheumatoid arthritis. A 48‐week double‐blind, prospective, placebo‐controlled study. Arthritis & Rheumatism. 36(11). 1501–1509. 116 indexed citations

Hannonen, Pekka, Mikko Hakola, Timo Möttönen, & M. Oka. (1989). Reactive Oligoarthritis Associated with Clostridium difficile Colitis. Scandinavian Journal of Rheumatology. 18(1). 57–60. 10 indexed citations

Hannonen, Pekka, S Tikanoja, Mikko Hakola, et al.. (1986). Urinary Neopterin Index as a Measure of Rheumatoid Activity. Scandinavian Journal of Rheumatology. 15(2). 148–152. 20 indexed citations

Hannonen, Pekka, Mikko Hakola, & M. Oka. (1985). Palindromic rheumatism in two non-identical brothers with identical HLA including DR4.. Annals of the Rheumatic Diseases. 44(3). 202–204. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact